

**UNITED STATES SECURITIES AND EXCHANGE
COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>STONE BENJAMIN</u> (Last) (First) (Middle) <u>10770 WATERIDGE CIRCLE, SUITE 210</u> (Street) <u>SAN CA 92121</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>04/20/2026</u>	3. Issuer Name and Ticker or Trading Symbol <u>First Tracks Biotherapeutics, Inc. [TRAX]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ <input checked="" type="checkbox"/> Officer (give title below) _____ Other (specify below) _____ <u>Chief Business Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year)
		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>17,262⁽¹⁾</u>	<u>D</u>	

**Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Employee Stock Option (right to buy)</u>	<u>(2)</u>	<u>06/14/2032</u>	<u>Common Stock</u>	<u>43,750</u>	<u>5.8</u>	<u>D</u>	
<u>Employee Stock Option (right to buy)</u>	<u>(3)</u>	<u>01/05/2033</u>	<u>Common Stock</u>	<u>48,300</u>	<u>6.22</u>	<u>D</u>	
<u>Employee Stock Option (right to buy)</u>	<u>(4)</u>	<u>01/02/2034</u>	<u>Common Stock</u>	<u>112,790</u>	<u>5.67</u>	<u>D</u>	
<u>Employee Stock Option (right to buy)</u>	<u>(5)</u>	<u>01/02/2035</u>	<u>Common Stock</u>	<u>92,500</u>	<u>3.97</u>	<u>D</u>	
<u>Employee Stock Option (right to buy)</u>	<u>(6)</u>	<u>01/05/2036</u>	<u>Common Stock</u>	<u>36,700</u>	<u>11.75</u>	<u>D</u>	
<u>Employee Stock Option (right to buy)</u>	<u>(7)</u>	<u>12/14/2032</u>	<u>Common Stock</u>	<u>3,100</u>	<u>7.66</u>	<u>D</u>	
<u>Restricted Stock Unit</u>	<u>(8)</u>	<u>(8)</u>	<u>Common Stock</u>	<u>4,425</u>	<u>(9)</u>	<u>D</u>	
<u>Restricted Stock Unit</u>	<u>(10)</u>	<u>(10)</u>	<u>Common Stock</u>	<u>20,605</u>	<u>(9)</u>	<u>D</u>	
<u>Restricted Stock Unit</u>	<u>(11)</u>	<u>(11)</u>	<u>Common Stock</u>	<u>24,337</u>	<u>(9)</u>	<u>D</u>	
<u>Restricted Stock Unit</u>	<u>(12)</u>	<u>(12)</u>	<u>Common Stock</u>	<u>27,100</u>	<u>(9)</u>	<u>D</u>	
<u>Performance Stock Unit</u>	<u>(13)</u>	<u>(13)</u>	<u>Common Stock</u>	<u>50,000</u>	<u>(14)</u>	<u>D</u>	

Explanation of Responses:

- Consists of shares of common stock received in connection with the spin-off of First Tracks Biotherapeutics, Inc. ("First Tracks") from AnaptysBio, Inc. ("AnaptysBio").
- The stock option vests as to 25% of the total shares on June 15, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

3. The stock option vests as to 25% of the total shares on January 6, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
4. The stock option vests as to 25% of the total shares on January 3, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
5. The stock option vests as to 25% of the total shares on January 7, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
6. The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
7. This stock option is fully vested.
8. The restricted stock units ("RSUs") vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
9. Each RSU represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration.
10. The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
11. The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
12. The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
13. Shares earned upon the vesting of a percentage of the performance stock units ("PSUs") granted to the Reporting Person on July 22, 2024. Each PSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of performance data metric goals ("Performance Metrics"). 50% of the total number of shares subject to the PSU shall vest each on July 1, 2025 and July 1, 2026 ("Vestings"), upon Performance Metrics achieved. If such Vestings do not occur, 100% of the PSUs shall fully vest on July 1, 2028. subject to the Reporting Person's service to the Issue on each vesting date.
14. Each PSU represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration.

Remarks:

On April 20, 2026, in connection with the AnaptysBio spin-off of First Tracks (the "Spin-Off"), AnaptysBio distributed all outstanding equity awards of First Tracks to the Reporting Person previously granted to the reporting person from AnaptysBio, which modification is intended to preserve the underlying value of the outstanding equity awards. The distributed equity awards remain subject to the same vesting conditions as those under the original equity awards.

/s/ Ajim Tamboli,
Attorney-in-Fact

04/22/2026

** Signature of Reporting
Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Dan Faga, Ajim Tamboli and Dave McKeon, and each of them, her true and lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as a representative of First Tracks Biotherapeutics, Inc. ("**Company**"), any and all Form 3, 4 or 5 reports required to be filed by the undersigned in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended ("**Exchange Act**"), and the rules thereunder with respect to transactions in securities of the Company;

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 report and timely file such report with the U.S. Securities and Exchange Commission and any stock exchange or similar authority; and

(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned, pursuant to this Power of Attorney, shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform each and every act and thing whatsoever requisite, necessary and proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or his substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that no such attorney-in-fact, in serving in such capacity at the request of the undersigned, is hereby assuming, nor is the Company hereby assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Form 3, 4 or 5 reports with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the 14th day of April, 2026.

/s/ Benjamin Stone

Name: Benjamin Stone